JP2013501816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501816A5 JP2013501816A5 JP2012524910A JP2012524910A JP2013501816A5 JP 2013501816 A5 JP2013501816 A5 JP 2013501816A5 JP 2012524910 A JP2012524910 A JP 2012524910A JP 2012524910 A JP2012524910 A JP 2012524910A JP 2013501816 A5 JP2013501816 A5 JP 2013501816A5
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- combination
- erythropoietin receptor
- medicament according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims description 20
- 102100036509 Erythropoietin receptor Human genes 0.000 claims description 20
- 239000012190 activator Substances 0.000 claims description 12
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 11
- 102000003951 Erythropoietin Human genes 0.000 claims description 10
- 108090000394 Erythropoietin Proteins 0.000 claims description 10
- 229940105423 erythropoietin Drugs 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 5
- 108010019673 Darbepoetin alfa Proteins 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000010437 erythropoiesis Effects 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 108700022380 synthetic erythropoiesis Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 108010074604 Epoetin Alfa Proteins 0.000 claims description 2
- 102100031939 Erythropoietin Human genes 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 claims description 2
- 206010061481 Renal injury Diseases 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000003173 antianemic agent Substances 0.000 claims description 2
- 229940115115 aranesp Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 claims description 2
- 229960005029 darbepoetin alfa Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960003388 epoetin alfa Drugs 0.000 claims description 2
- 108010002601 epoetin beta Proteins 0.000 claims description 2
- 229960004579 epoetin beta Drugs 0.000 claims description 2
- 108010067416 epoetin delta Proteins 0.000 claims description 2
- 229950002109 epoetin delta Drugs 0.000 claims description 2
- 108010090921 epoetin omega Proteins 0.000 claims description 2
- 229950008767 epoetin omega Drugs 0.000 claims description 2
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 208000037806 kidney injury Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 14
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 238000011284 combination treatment Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2009/004659 WO2010019261A1 (en) | 2008-08-14 | 2009-08-13 | Use of gdf traps to increase red blood cell levels |
| USPCT/US2009/004659 | 2009-08-13 | ||
| US12/583,177 | 2009-08-13 | ||
| US12/583,177 US8058229B2 (en) | 2008-08-14 | 2009-08-13 | Method of increasing red blood cell levels or treating anemia in a patient |
| US30590110P | 2010-02-18 | 2010-02-18 | |
| US61/305,901 | 2010-02-18 | ||
| PCT/US2010/045509 WO2011020045A1 (en) | 2009-08-13 | 2010-08-13 | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236828A Division JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013501816A JP2013501816A (ja) | 2013-01-17 |
| JP2013501816A5 true JP2013501816A5 (enExample) | 2013-09-19 |
| JP5909446B2 JP5909446B2 (ja) | 2016-04-26 |
Family
ID=43586530
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524910A Active JP5909446B2 (ja) | 2009-08-13 | 2010-08-13 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2015236828A Withdrawn JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2018153528A Active JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2020163806A Pending JP2020203953A (ja) | 2009-08-13 | 2020-09-29 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236828A Withdrawn JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2018153528A Active JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2020163806A Pending JP2020203953A (ja) | 2009-08-13 | 2020-09-29 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP3117829B1 (enExample) |
| JP (4) | JP5909446B2 (enExample) |
| KR (5) | KR101882521B1 (enExample) |
| CN (7) | CN113082194B (enExample) |
| AU (1) | AU2010282361B2 (enExample) |
| BR (2) | BR122020019169B1 (enExample) |
| CA (1) | CA2770822C (enExample) |
| ES (2) | ES2796121T3 (enExample) |
| IL (6) | IL287990B (enExample) |
| MX (2) | MX2012001916A (enExample) |
| NZ (3) | NZ623113A (enExample) |
| RU (2) | RU2642302C1 (enExample) |
| WO (1) | WO2011020045A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3059245B1 (en) | 2004-07-23 | 2018-11-07 | Acceleron Pharma Inc. | Actrii receptor antagonistic antibodies |
| MX2008006626A (es) | 2005-11-23 | 2008-09-24 | Acceleron Pharma Inc | Antagonistas de activin-actriia y usos para promover el crecimiento de huesos. |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| WO2008094708A2 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI606062B (zh) | 2007-02-09 | 2017-11-21 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| WO2009038745A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| HRP20191109T1 (hr) | 2008-08-14 | 2019-09-20 | Acceleron Pharma Inc. | Gdf klopke za uporabu u liječenju anemije |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| AU2010258931B2 (en) | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JP2014502260A (ja) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ， インコーポレイテッド | Ａｃｔｒｉｉａ結合剤およびその使用 |
| EA202090053A3 (ru) * | 2011-10-17 | 2020-06-30 | Акселерон Фарма, Инк. | Способы и композиции для лечения неэффективного эритропоэза |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| IL290653B2 (en) * | 2012-10-24 | 2025-05-01 | Celgene Corp | Biomarker for use in the treatment of anemia |
| AU2013334660B2 (en) * | 2012-10-24 | 2018-08-09 | Celgene Corporation | Methods for treating anemia |
| ES2884095T3 (es) | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
| JP2017509647A (ja) * | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| MA40008A (fr) * | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| WO2016069925A1 (en) | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| AU2015358469B2 (en) | 2014-12-03 | 2021-05-27 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for treating anemia |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| WO2016128523A1 (en) * | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| SG10201913747PA (en) | 2015-04-22 | 2020-03-30 | Biogen Ma Inc | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| JP2018522579A (ja) | 2015-05-20 | 2018-08-16 | セルジーン コーポレイション | アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 |
| WO2017079591A2 (en) * | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| AU2016359695A1 (en) | 2015-11-23 | 2018-06-14 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| US20170240639A1 (en) * | 2016-02-22 | 2017-08-24 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
| HUE054228T2 (hu) | 2016-07-15 | 2021-08-30 | Acceleron Pharma Inc | Használható actriia polipeptideket tartalmazó összetételek a pulmonalis hypertónia kezelésében történõ alkalmazásra |
| PL3490582T3 (pl) * | 2016-07-27 | 2024-09-23 | Acceleron Pharma Inc. | Kompozycje do zastosowania w leczeniu mielofibrozy |
| CN110036025B (zh) | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
| EP3522934A4 (en) | 2016-10-05 | 2020-04-15 | Acceleron Pharma Inc. | COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASES |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| PT3638243T (pt) | 2017-06-14 | 2024-10-31 | Celgene Corp | Métodos para tratamento da mielofibrose e anemia associadas ao neoplasma mieloproliferativo |
| JP7258021B2 (ja) | 2017-11-09 | 2023-04-14 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体を含む医薬組成物 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| CN112601538B (zh) * | 2018-05-09 | 2025-08-19 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| US12310982B2 (en) | 2018-12-10 | 2025-05-27 | Elena Valentinovna ARSHINTSEVA | Use of the poloxamer as a pharmacologically active substance |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CN111466337B (zh) * | 2020-05-19 | 2022-04-19 | 山东大学齐鲁医院 | 一种腹主动脉瘤动物模型及其构建方法 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN115317589B (zh) * | 2022-09-05 | 2024-12-13 | 中国海洋大学 | 脯氨酰羟化酶抑制剂及其应用 |
| CN119198238A (zh) * | 2024-09-18 | 2024-12-27 | 广东省安家医健健康管理有限公司 | 一种地中海贫血检测系统及试剂盒 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| DE69636866D1 (en) | 1995-04-11 | 2007-03-15 | Gen Hospital Corp | Reverse "two-hybrid"-systeme |
| CA2359242C (en) | 1999-01-21 | 2009-12-08 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
| PT1311285E (pt) * | 2000-05-15 | 2005-06-30 | Hoffmann La Roche | Composicao farmaceutica liquida contendo um derivado de eritropoietina |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| CN100522946C (zh) * | 2001-12-06 | 2009-08-05 | 法布罗根股份有限公司 | 低氧诱导因子(HIF)α的稳定化 |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| WO2004069237A1 (en) * | 2003-02-07 | 2004-08-19 | Prometic Biosciences Inc. | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis |
| GB0304424D0 (en) * | 2003-02-26 | 2003-04-02 | Glaxosmithkline Biolog Sa | Novel compounds |
| EP3059245B1 (en) | 2004-07-23 | 2018-11-07 | Acceleron Pharma Inc. | Actrii receptor antagonistic antibodies |
| EP1819357A4 (en) * | 2004-12-09 | 2009-02-25 | Univ Pittsburgh | VACCINES FOR FAST RESPONSE TO A BIRD GRIP PANDEMY |
| WO2006115274A1 (ja) * | 2005-04-26 | 2006-11-02 | Ajinomoto Co., Inc. | 骨髄赤血球前駆細胞分化促進剤 |
| AU2006301582B2 (en) * | 2005-10-07 | 2011-10-13 | Msd Italia S.R.L. | Matrix metalloproteinase 11 vaccine |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008073292A2 (en) * | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
| PL2124999T3 (pl) * | 2006-12-18 | 2013-03-29 | Acceleron Pharma Inc | Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| KR20190049912A (ko) * | 2008-06-26 | 2019-05-09 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| HRP20191109T1 (hr) * | 2008-08-14 | 2019-09-20 | Acceleron Pharma Inc. | Gdf klopke za uporabu u liječenju anemije |
-
2010
- 2010-08-13 KR KR1020127004678A patent/KR101882521B1/ko active Active
- 2010-08-13 CN CN202110417494.3A patent/CN113082194B/zh active Active
- 2010-08-13 KR KR1020187020803A patent/KR20180085825A/ko not_active Ceased
- 2010-08-13 BR BR122020019169-4A patent/BR122020019169B1/pt active IP Right Grant
- 2010-08-13 RU RU2016123808A patent/RU2642302C1/ru active
- 2010-08-13 KR KR1020197027722A patent/KR102170682B1/ko active Active
- 2010-08-13 MX MX2012001916A patent/MX2012001916A/es active IP Right Grant
- 2010-08-13 NZ NZ623113A patent/NZ623113A/en unknown
- 2010-08-13 AU AU2010282361A patent/AU2010282361B2/en active Active
- 2010-08-13 CN CN201080045618.XA patent/CN102655872B/zh active Active
- 2010-08-13 CN CN202110421547.9A patent/CN113171442B/zh active Active
- 2010-08-13 KR KR1020207030283A patent/KR20200124322A/ko not_active Ceased
- 2010-08-13 NZ NZ598348A patent/NZ598348A/en unknown
- 2010-08-13 KR KR1020227045338A patent/KR102606494B1/ko active Active
- 2010-08-13 JP JP2012524910A patent/JP5909446B2/ja active Active
- 2010-08-13 WO PCT/US2010/045509 patent/WO2011020045A1/en not_active Ceased
- 2010-08-13 ES ES10808838T patent/ES2796121T3/es active Active
- 2010-08-13 CN CN201510979350.1A patent/CN105561295B/zh active Active
- 2010-08-13 IL IL287990A patent/IL287990B/en unknown
- 2010-08-13 RU RU2012109393/10A patent/RU2592670C2/ru active
- 2010-08-13 NZ NZ712943A patent/NZ712943A/en unknown
- 2010-08-13 CN CN202110879546.9A patent/CN113577291A/zh active Pending
- 2010-08-13 CN CN201510979490.9A patent/CN105535938B/zh active Active
- 2010-08-13 EP EP16186033.3A patent/EP3117829B1/en active Active
- 2010-08-13 ES ES16186033T patent/ES2844123T3/es active Active
- 2010-08-13 EP EP10808838.6A patent/EP2464369B1/en active Active
- 2010-08-13 CN CN201510979291.8A patent/CN105412908B/zh active Active
- 2010-08-13 EP EP20197940.8A patent/EP3838919A1/en not_active Withdrawn
- 2010-08-13 BR BR112012003232-1A patent/BR112012003232B1/pt active IP Right Grant
- 2010-08-13 CA CA2770822A patent/CA2770822C/en active Active
-
2012
- 2012-02-12 IL IL218052A patent/IL218052A/en active IP Right Grant
- 2012-02-13 MX MX2019010341A patent/MX2019010341A/es unknown
-
2015
- 2015-12-03 JP JP2015236828A patent/JP2016034981A/ja not_active Withdrawn
-
2017
- 2017-05-01 IL IL25204417A patent/IL252044B/en active IP Right Grant
- 2017-05-01 IL IL252045A patent/IL252045B/en active IP Right Grant
- 2017-05-01 IL IL252046A patent/IL252046B/en active IP Right Grant
-
2018
- 2018-08-17 JP JP2018153528A patent/JP6860533B2/ja active Active
-
2020
- 2020-07-05 IL IL275851A patent/IL275851B/en unknown
- 2020-09-29 JP JP2020163806A patent/JP2020203953A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501816A5 (enExample) | ||
| Parvez et al. | PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment | |
| Hamid et al. | Intratumoral immunotherapy—update 2019 | |
| RU2012109393A (ru) | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов | |
| Arnold et al. | The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules | |
| Adamali et al. | Current and novel drug therapies for idiopathic pulmonary fibrosis | |
| Chuntova et al. | Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy | |
| Koh et al. | Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage | |
| US10525106B2 (en) | Angiopoietin-based interventions for treating cerebral malaria | |
| JP2017533910A5 (enExample) | ||
| Gholami et al. | A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer | |
| WO2015024667A8 (en) | Method for increasing expression of rna-encoded proteins | |
| Mofarrahi et al. | Regulation of angiopoietin expression by bacterial lipopolysaccharide | |
| Brunckhorst et al. | Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis | |
| Samuel et al. | Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2017501381A5 (enExample) | ||
| Wei et al. | Pioglitazone alleviates cardiac fibrosis and inhibits endothelial to mesenchymal transition induced by pressure overload | |
| Greene et al. | Targeting transcription factors ATF5, CEBPB and CEBPD with cell-penetrating peptides to treat brain and other cancers | |
| JP2017530130A5 (enExample) | ||
| Sharma | Interleukin-6 trans-signaling: a pathway with therapeutic potential for diabetic retinopathy | |
| JP2020517658A5 (enExample) | ||
| Ding et al. | Anti‑neuropilin‑1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation | |
| JP2015514115A5 (enExample) | ||
| Nowacka et al. | Angiogenesis in glioblastoma—treatment approaches |